Lucira Health Shares Double on Diagnostic Tests FDA Authorization
25 2월 2023 - 7:43AM
Dow Jones News
By Denny Jacob
Lucira Health Inc. shares doubled in after-hours trading Friday
following the Food and Drug Administration's emergency use
authorization for its diagnostic test.
The FDA said it authorized the Lucira COVID-19 & Flu Test,
an over-the-counter at-home test that can differentiate and detect
the flu and the virus that causes Covid-19.
"The FDA strongly supports innovation in test development, and
we are eager to continue advancing greater access to at-home
infectious disease testing to best support public health needs,"
said Jeff Shuren, director of the FDA's center for devices and
radiological health.
Lucira, the publicly traded maker of at-home Covid-19 testing
kits, this week filed for bankruptcy, saying an easing of pandemic
restrictions has lowered demand for its products. The company,
which lists $145.9 million in assets and $84.7 million in debt,
said Wednesday it will look for a buyer while continuing to serve
customers during chapter 11 proceedings in U.S. Bankruptcy Court in
Wilmington, Del.
Shares rose 113% to 30 cents in aftermarket trading. The stock,
which closed up 13% to 14 cents, is down about 97% over the last 12
months.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 24, 2023 17:28 ET (22:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Lucira Health (NASDAQ:LHDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Lucira Health (NASDAQ:LHDX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Lucira Health Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Lucira Health Inc News Articles